clinical trial · NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
European Myeloma Network B.V.·phase3·recruiting·n = 1,594
Multiple MyelomaTeclistamabLenalidomide
brief summary
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
started
Sep 8, 2022
primary completion
Apr 1, 2028
completion
Apr 1, 2032
last updated
Mar 25, 2026
official title
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol